Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: A topical skin protectant formulation containing a barrier cream and a active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWAs). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: This invention pertains in part to a method for delivering functional DNA or antigens. The desired DNA is introduced into attenuated bacteria able to enter cells. Once the bacteria is in the cell, antimicrobial agents are introduced such that they enter the mammalian cell and lyse the bacteria thereby allowing the delivery of carried functional DNA or antigens. The advantages of this method and its uses are described.

Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA's). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: Biodegradable pharmaceutical compositions and method for treating bacterial infections therein.

Abstract: Compounds of the formula: wherein R1 and R2 are alkyl of 1-8 carbons have been shown to have both neuroprotective and analgesic activities. The compounds of the invention may be used in treatment of conditions that would normally result in neuronal damage, including those arising on account of cerebral ischemia/hypoxia or increase in intracranial pressure such as neoplasms, stroke, meningitis or trauma and for treatment of pain. Compositions of the invention can also be useful for treatment of toxin-related damage such as drug over-dose or exposure to toxins in the environment.

Abstract: Methods, compositions and materials useful in the detection of organophosphorous and organosulfur compounds are disclosed. In particular, biosensors wherein a porous or a non-porous support having an enzyme immobilized upon or within are disclosed. The biosensors exhibit enzymatic stability at extreme temperatures and/or denaturing conditions, and similar kinetic characteristics of the soluble form of the enzymes utilized. The enzyme does not leach from the porous or non-porous support and the material retains enzymatic activity after prolonged storage. Differential biosensors are also disclosed.

Abstract: A C-reactive protein concentration level test and kit for on-site determination of C-reactive protein levels in biological samples is disclosed.

Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA's). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: Novel antiparasitic and antifungal compositions are disclosed. The antiparasitic and antifungal compositions are useful for human and veterinary therapy for the treatment and/or prevention of parasitic infection. Also disclosed are novel mechanisms of identifying antifungal and antiparasitic compositions by their biochemical action on lipid synthesis and/or metabolism and/or excretion.

Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.

Abstract: Provided is a breeding container which is adapted to be lethal to container breeding mosquitoes which contains: a walled structure defining an internal volume, the walled structure being constructed and arranged to contain an aqueous liquid within at least a portion of the internal volume; at least one opening in the walled structure disposed so as to allow mosquitoes to enter the walled structure; mosquito egg laying structure in the internal volume constructed and arranged such that female mosquitoes contact a surface of the mosquito egg laying structure; and an insecticide that is lethal to mosquitoes present in an amount sufficient to kill the female mosquitoes in contact with the surface. Also provided is a lethal mosquito breeding container kit and a method for controlling the population of container breeding mosquitoes.

Abstract: A method of making a vaccine for anthracis that inolves a bacterial expression system and production and use of protective antigen (PA) against Bacillus anthracis. The PA immunogen is useful in a vaccine against human anthrax. The PA can be produced by an asporogenic organism which produces the desired antigen, which is then harvested from the supernatant.

Abstract: A method of diagnosing exposure to a toxic agent comprising the steps of detecting the amount of protein/gene expression present in a sample of mammalian tissue or mammalian body fluids that has not been exposed to a toxic agent. Then the amount of protein/gene expression present in a sample of mammalian tissue or mammalian body fluids that has been exposed to the toxic agent is detected. A determination of the difference in the detected amount of protein/gene expression between the exposed and unexposed samples is made. A comparison of the difference to a library of expected protein/gene expression for predetermined toxic agents is made. Finally, an evaluation is made whether the difference indicates the exposure to a particular toxic agent. A treatment method for administering a therapeutic agent which inhibits the mechanistic pathways necessary to maintain the progression of lethal shock is also disclosed.

Abstract: An attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell is disclosed. A Japanese encephalitis vaccine comprising said attenuated virus is also disclosed.

Abstract: Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.

Abstract: A live attenuated Venezuelan equine encephalitis virus (VEE) is described which comprises a viral gene rearrangement. This rearranged attenuated virus is useful as vaccine for protection against infection with VEE. Methods of preparing the virus and methods of using the virus are described.

Abstract: Methods for developing vaccines to protect from neurotoxins of C. botulinum have been developed. Truncated BoNT/A proteins of about 15-30 kDa in size produced immune responses that provided protection from neuronal damage by botulinum neurotoxins.